Clinical trials: Stage II Breast Carcinoma
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer
This clinical trial evaluates whether engineering gut microbiome using probiotics will alter the body's immune system to react to stage I-III breast or lung cancers that can be removed by surgery (operable).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma
- Trial name
- NCT04857697
- Testing
- Biopsy, Biospecimen Collection, Probiotic
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
HER2-negative Breast Cancer, Advanced Breast Cancer
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
This is a phase II, multicenter, open-label, randomized controlled trial to compare the efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in previously treated, HER2-negative locally advanced or…
- Trial name
- ORIENTA (NCT06102824)
- Testing
- Organoid-guided treatment, Taxane, Capecitabine
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00324324
- Testing
- moxifloxacin hydrochloride
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- OHSU Knight Cancer Institute
Triple Negative Breast Cancer, HER2-positive Breast Cancer
Study of Screening Brain MRIs in Stage IV Breast Cancer
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
- Conditions
- Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer
- Trial name
- NCT05115474
- Testing
- Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Stage II Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT)
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- MARGOT (NCT04425018)
- Testing
- Paclitaxel, Pertuzumab, Margetuximab
- Where
- 14 sites in United States
- Volunteers
- 174 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression.
- Trial name
- NCT02291913
- Testing
- Everolimus, Exemestane, Tamoxifen
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer
Purpose: To determine whether [18F]FES can predict clinical benefit (defined as complete response, partial response and stable disease ≥ 6 months) to fulvestrant (250 mg IM q 28 days) in post-menopausal women with recurrent or…
- Trial name
- NCT00816582
- Testing
- Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline, Diagnostic Imaging: 18F-FES PET/CT - Baseline, Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up
- Where
- 4 sites in Canada
- Volunteers
- 17 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093808
- Testing
- trastuzumab, capecitabine, vinorelbine tartrate
- Where
- 147 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Breast Cancer
Biomarkers in Blood Samples From Older Breast Cancer Survivors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01138345
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
- Trial name
- NCT05041101
- Testing
- Eribulin Mesylate, Grapiprant
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT06058377
- Testing
- Biospecimen Collection, Cyclophosphamide, Doxorubicin
- Where
- 564 sites in United States, Puerto Rico
- Volunteers
- 3,680 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic (Stage IV) Melanoma
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body).
- Trial name
- EPIBREAST (NCT07340619)
- Testing
- prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant
- Where
- 8 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
Breast Cancer
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
The aim of this international open-label randomized phase II trial is to evaluate the efficacy and safety of an all-oral combination and two all-intravenous combinations as first-line therapy for HER2-negative mBC patients.
- Trial name
- NCT03887130
- Testing
- oral vinorelbine, Capecitabine, Gemcitabine 1250 mg/m²
- Volunteers
- 152 people
- Sponsor
- Pierre Fabre Medicament
Breast Cancer
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the…
- Trial name
- NCT00462865
- Testing
- Gemcitabine and Capecitabine and Avastin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003519
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 134 sites in United States
- Volunteers
- 2,778 people
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Breast Cancer
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
Protocol Title: A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor
- Trial name
- Post-CDK (NCT05536128)
- Testing
- Olaparib, Fulvestrant
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Seoul National University Hospital
Breast Neoplasms
Trial of Tomotherapy in Breast Cancer
Tomotherapy is a new radiation therapy system that uses an integrated CT scanner during delivery of radiation treatment to improve the accuracy of the treatment.
- Trial name
- TomoBreast (NCT00459628)
- Testing
- Conventional radiotherapy, Tomotherapy
- Where
- Belgium
- Volunteers
- 118 people
- Sponsor
- Vrije Universiteit Brussel
Breast Cancer
Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00381901
- Testing
- trastuzumab, polymorphism analysis, adjuvant therapy
- Where
- 82 sites in France
- Volunteers
- 3,400 people
- Sponsor
- National Cancer Institute, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.